Just an average investor... primarily in American equity and bonds. (Important Note: My articles, blogs, comments, reference links and messages are not intended to be investment advisements; or to value securities. Examples and considerations are hypothetical and educational. Please consult a financial advisor before making investments in any security. Thank you for reading!)
Nelson Alves is a professional investor, established in Portugal. He started his career in 2007 right at the start of the biggest financial crisis since 1929. Until 2011 he worked in several trading desks. His main influences are Philip Fisher and Warren Buffet. Nelson is looking to help small investors on the task of preserving and increasing their savings’ funds.
Being a thoroughly student of several investment approaches, he believes that the equity markets should be on service of both small and institutional investors, and therefore every citizen should be able to reclaim his fair share of the long-term growing prosperity around the world.
Software Engineer - late 50s
Like to hold a combination of index funds (when appropriate), short-term bonds, some managed funds, and a focused selection of individual stocks (preferably with no more debt that 4 times annual earnings)
Prefer simple to understand stocks, no biotech and minimal tech individual stock holdings.
I'm the author of six published books, an investor, and a cancer survivor. I got my start thirty-two years ago ghost-writing for a UCLA econ. prof who owned a popular stock-picking newsletter. I have been extensively involved in clinical research (consulted with various medical colleges on new technologies) as well as a speaker in post-doctoral continuing ed in the US, UK, and Canada. Right now, I'm re-editing books for publication and writing articles on Seeking Alpha for others who (like me) enjoy doing extensive investment research and profiting from it.
Over 20 years experience as an equity analyst/portfolio manager, convertible portfolio manager, high yield/leverage loan credit analyst, and banking/credit analyst at several financial institutions. Strong expertise in following healthcare companies in all sub-sectors and market capitalization. Also, have covered telecommunications, technology, consumer cyclical and consumer staples companies as well.
MTR Investors Group was founded in mid 2008. Since that time our primary goal is to provide powerful and profitable investment research tools to stock and option investors/traders. We do not provide buy or sell recommendations on any stock, etf, or other investments. We simply provide powerful tools for stock and option investors and traders.
The following are the primary tools we provide (we also provide economic models and advanced charting):
I. Expert Option Search
Our Credit Spread. Iron Condor, Covered Call and Cash Secured Put screener is one of the most powerful tools we provide to the individual investor. Powerful features such probability of assignment, downside protection, and many others. Our screener helps option traders make the best decision possible when writing Covered Calls, Naked Puts, Credit Spreads, and Iron Condors.
Many investors use our option screener to monitor a long term portfolio and select the best covered calls to sell on their portfolios.
Option Writers/Sellers use our option screener to find options with the highest probability of expiring worthless.
II. Stock Miner
Stock Miner is use to analyze stocks from a monthly and weekly historical performance. We use Stock Miner for weekly and monthly trade setups.
III. Stock Market Scout (SMS) & Stock Market Level (SML)
We use SMS as a model to indicate allocating cash to an index ETF (such as SPY) by going long on Green, cash on Yellow, short on Red (or stay in cash). We use SML to indicate if the market is overbought or oversold. This is not a recommendation to buy or sell SPY.
I founded Retail Investor 360 and Vincata Enterprises LLC in 2013 to help everyday investors invest prudently as well as to assist life science firms gain exposure to the investing community. The ultimate results are two prongs: more lifesaving medicine for patients and market intelligence for investors.
My diverse background as an independent financial analyst, medical doctor, entrepreneur and chemistry instructor complements the integrated investing research that I pioneered.
The first rule of integrated investing is to realized one’s limitation. For instance, physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers typically do not possess the medical expertise of healthcare providers. Likewise, scientists are skillful in data analysis but they may not be familiar with prescribing patterns.
The second rule is to move beyond one’s circles of competence through learning various disciplines as well as leveraging on others’ expertise. In doing so, I tap into the intelligence of physicians, financiers and scientists in my network.
The third rule is to seek intelligence not available on the balance sheet via conducting field research. Accordingly, I gained much insight through informal patient as well as consumer surveys. If needed, I run my own statistical tests.
All that being said, integrated investing research helped me to accurately forecast the outcomes of numerous clinical trials like the Flint of Intercept, Ascend of InterMune and Affinity of MannKind, far in advance of the market.
Despite my focus on the life science sector, I cover other industries from time to time. And my work has expanded to assisting not only retail investors but professionals as well. I mostly publish long investing theses, as the rewards are most substantial. Nonetheless, I issue short theses once in a blue moon. This is not to short firms but to sharpen the skills needed to lead readers away from cautious investing.
Interestingly, my overall accuracy in the short thesis has been far better than the long counterparts. It is imperative for the readers to realize that one does not need to achieve 100 percent accurate results. The keys are to maintain this above average accuracy and to have adequate portfolio diversification. As long as you are right six out of ten times, you should achieve market outperformance in the long run.
Please note that I am not a registered investment advisor. Even if I am, you still need to consult with your own financial advisor, as your circumstance can be different from someone else’s. My research are not recommendations to buy, sell or transact any forms of security. And though I strive to provide the most accurate information available, the nature of information changes over time. Therefore, I can neither guarantee the accuracy nor timeliness of such information that, in and of themselves, are presented “as is.” You should use my articles as educational and informational materials to assist you in your own due diligence.
I also write for Talkmarkets from time to time. You can check out my articles at http://www.talkmarkets.com/contributor/Retail-Investor-360/